Roles of long non‑coding RNA SNHG16 in human digestive system cancer (Review).


Journal

Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 23 05 2023
accepted: 26 04 2024
medline: 28 6 2024
pubmed: 28 6 2024
entrez: 28 6 2024
Statut: ppublish

Résumé

The incidence of tumors in the human digestive system is relatively high, including esophageal cancer, liver cancer, pancreatic cancer, gastric cancer and colorectal cancer. These malignancies arise from a complex interplay of environmental and genetic factors. Among them, long non‑coding RNAs (lncRNAs), which cannot be translated into proteins, serve an important role in the development, progression, migration and prognosis of tumors. Small nucleolar RNA host gene 16 (SNHG16) is a typical lncRNA, and its relationship with digestive system tumors has been widely explored. The prevailing hypothesis suggests that the principal molecular mechanism of SNHG16 in digestive system tumors involves it functioning as a competitive endogenous RNA that interacts with other proteins, regulates various genes and influences a downstream target molecule. The present review summarizes recent research on the relationship between SNHG16 and numerous types of digestive system cancer, encompassing its biological functions, underlying mechanisms and potential clinical implications. Furthermore, it outlines the association between SNHG16 expression and pertinent risk factors, such as smoking, infection and diet. The present review indicated the promise of SNHG16 as a potential biomarker and therapeutic target in human digestive system cancer.

Identifiants

pubmed: 38940337
doi: 10.3892/or.2024.8765
pii: 106
doi:
pii:

Substances chimiques

RNA, Long Noncoding 0
SNHG16 lncRNA, human 0
Biomarkers, Tumor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Lujie Zhao (L)

School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.

Yuling Kan (Y)

Central Laboratory of Binzhou People's Hospital, Binzhou, Shandong 256600, P.R. China.

Lu Wang (L)

School of Clinical Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.

Jiquan Pan (J)

School of Clinical Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.

Yun Li (Y)

School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.

Haiyan Zhu (H)

Department of Medical Oncology, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China.

Zhongfa Yang (Z)

School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.

Lin Xiao (L)

School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.

Xinhua Fu (X)

School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.

Fujun Peng (F)

School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.

Haipeng Ren (H)

Department of Medical Oncology, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH